## InMed Pharmaceuticals Faces Nasdaq Delisting Notice After Failing to Meet Minimum Bid Price Requirement
InMed Pharmaceuticals Inc. has been formally notified by The Nasdaq Stock Market that it is not in compliance with a critical listing standard, triggering a potential delisting. The company's common stock failed to maintain a minimum bid price of $1.00 per share over a consecutive 30-day trading period, a violation of Nasdaq Listing Rule 5550(a)(2). This notice places the company on a 180-day compliance clock, during which its shares must close at or above the $1.00 threshold for a minimum of ten consecutive business days to regain standing.

The filing, an 8-K submitted to the SEC, confirms the receipt of the deficiency notice on March 26, 2026. This administrative action does not immediately affect the trading of InMed's common stock, which will continue to be listed on The Nasdaq Capital Market under the symbol "INM" for the time being. However, the notice represents a significant regulatory and market credibility challenge for the biopharmaceutical firm, which focuses on cannabinoid-based drug development.

Failure to regain compliance within the allotted 180-day period could lead to the delisting of InMed's securities from Nasdaq. In such a scenario, the company's stock would likely be quoted on an over-the-counter market, which typically carries higher volatility, lower liquidity, and diminished visibility among institutional investors. This development places immediate pressure on company management to execute a strategic response, which may include a reverse stock split, to meet the exchange's minimum bid requirement and preserve its Nasdaq listing.
---
- **Source**: SEC EDGAR
- **Sector**: The Vault
- **Tags**: Nasdaq, Delisting, SEC Filing, Compliance, Biopharma
- **Credibility**: unverified
- **Published**: 2026-03-30 22:26:59
- **ID**: 41894
- **URL**: https://whisperx.ai/en/intel/41894